ClinicalTrials.gg
RecruitingNCT05669950Updated Mar 9, 2026

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

A Phase 1/2 interventional study of Lu AG13909 in Congenital Adrenal Hyperplasia, sponsored by H. Lundbeck A/S. Recruiting at 17 sites in 9 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by H. Lundbeck A/S · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2022; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Adrenal Hyperplasia, Congenital with a site in France — 6 open to participants now, 8 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · France.

Planned enrollment
8th of 11
42 · median 76
Started
2022
with 2 others
Phase 1/2
Only one
of the 21
Registered
15th of 21
by date
Lead sponsor
1 of 21
H. Lundbeck A/S

Among the 21 studies in Adrenal Hyperplasia, Congenital with a site in France, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2022, is the only one in phase 1/2, and was the 15th registered.

Adrenal Hyperplasia, Congenital

101 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 28 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

6 of the 21 studies in Adrenal Hyperplasia, Congenital with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Adrenal Hyperplasia, Congenital with a site in France, or all of them as a file.
02

Study summary

This trial will evaluate the effects of different doses of Lu AG13909 in adult participants with congenital adrenal hyperplasia, also called CAH. CAH is a rare genetic disorder that affects a person's ability to produce certain hormones. The main goals of this trial are to learn about the safety and tolerability of Lu AG13909, how Lu AG13909 behaves in the body, and how the body responds to Lu AG13909.

03

Conditions studied

  • Congenital Adrenal Hyperplasia
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Parts A and B:

  • Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and/or elevated 17-OHP).
  • Morning (pre- [GC] replacement dose) blood concentrations of 17-OHP >4-times (ULN).
  • (BMI) ≥18.5 kilograms (kg)/square meter (m\^2) (minimum 50 kg) and ≤40 kg/m\^2.
  • Stable GC replacement therapy for ≥1 month prior to the Screening Visit.
  • For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥3 months prior to the Screening Visit.
  • Apart from CAH, the participant is generally healthy in the opinion of the investigator and based on medical history, physical examination, vital signs, ECGs, and the results of the safety laboratory tests.

Part C:

  • Confirmed diagnosis of 21-hydroxylase deficiency CAH (based on a pathogenic CYP21A2 variant and/or elevated 17-OHP).
  • For Cohort C1 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) > ULN for age and sex.
  • For Cohort C2 only: Morning (pre-GC replacement dose) blood concentrations of androgens (A4) ≤ ULN for age and sex and the participant is treated with high doses of GC.
  • Stable GC replacement therapy for ≥1 month prior to the Screening Visit.
  • For the salt-wasting form of CAH, the participant must have been on a stable dose of mineralocorticoid replacement for ≥1 month prior to the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • The participant is pregnant or breastfeeding.
  • The participant has a abnormal laboratory value, (ECG) parameter, or vital signs value, or other safety findings at the Screening Visit that indicate a potential risk for the participant if enrolled, in the opinion of the investigator.
  • The participant has a history of known or intolerance to Lu AG13909 or its .

Part C Only:

  • The participant has received at least one dose of Lu AG13909 in Part A or Part B.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Lu AG13909

    Participants in Part A will receive multiple intravenous (IV) doses of Lu AG13909 per a prespecified dosing schedule. After data from Part A has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part B will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule. After data from Part B has shown that a pharmacologically relevant dose level is safe and tolerable, participants in Part C will then receive multiple IV doses of Lu AG13909 per a prespecified dosing schedule. Participants from Part C may be eligible to continue in the optional Treatment Extension.

    Drug: Lu AG13909

Interventions

06

What researchers measure

Primary outcomes

  1. Parts A and B: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Up to Day 161

  2. Parts A and B: Number of Participants With Anti-Drug Antibodies (ADAs)

    Time frame: Day 1 up to Day 161

  3. Parts A and B: Cmax: Maximum Observed Serum Concentration of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  4. Parts A and B: Tmax: Nominal Time Corresponding to the Occurrence of Cmax

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  5. Parts A and B: Ctrough: Minimum Observed Serum Concentration of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  6. Parts A and B: t½: Apparent Elimination Half-life of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  7. Parts A and B: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  8. Parts A and B: CL: Apparent Total Serum Clearance of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  9. Parts A and B: Vz: Volume of Distribution During the Terminal Elimination Phase After IV Administration of Lu AG13909

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  10. Parts A and B: Change From Baseline After Each Dose of Lu AG13909 in Blood Concentrations of 17-hydroxyprogesterone (17-OHP) and Androstenedione (A4)

    Time frame: Baseline up to Day 85

  11. Parts A and B: AUC0-tau: Area under the curve over a dosing interval

    Time frame: 0 (predose) up to 24 hours postdose on Day 1 to Day 161

  12. Part C: Morning Concentration of A4 in Blood <Upper Limit of Normal (ULN)

    Time frame: Day 169

Secondary outcomes

  1. Part C: Lu AG13909 Serum Concentrations Following Multiple IV Doses

    Time frame: Baseline up to Day 352

  2. Part C: Change From Baseline of Lu AG13909 in Blood Concentrations of 17-OHP and A4

    Time frame: Baseline up to Day 169

  3. Part C: Number of Participants With TEAEs

    Time frame: Baseline up to Day 352

  4. Part C: Number of Participants With ADAs

    Time frame: Baseline up to Day 352

07

Study locations

17 of 17 sites recruiting
  • University Hospital-University of Michigan
    Ann Arbor, Michigan 48109, United States
    Recruiting
  • Rigshospitalet
    Copenhagen, 2100, Denmark
    Recruiting
  • Chu Angers
    Angers, 49933, France
    Recruiting
  • CHU de Lille
    Lille, 59000, France
    Recruiting
  • GH Pitié-Salpêtrière
    Paris, 75013, France
    Recruiting
  • CHRU Strasbourg
    Strasbourg, 67091, France
    Recruiting
  • David Metreveli Medical Centre, Tbilisi
    Tbilisi, 0144, Georgia
    Recruiting
  • Beaumont Hospital Royal College of Surgeons in Ireland (RCSI), Dublin
    Dublin, D02 YN77, Ireland
    Recruiting
  • Azienda Ospedaliero Universitaria di Bologna
    Bologna, 40138, Italy
    Recruiting
  • Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma
    Roma, 00161, Italy
    Recruiting
  • Centrum Nowoczesnych Terapii, Dobry Lekarz
    Dobry Lekarz, 60-324, Poland
    Recruiting
  • Sahlgrenska University Hospital
    Gothenburg, 413 45, Sweden
    Recruiting
  • Karolinska University Hospital
    Stockholm, 17174, Sweden
    Recruiting
  • NIHR/Wellcome Trust Clinical Research Facility
    Birmingham, B15 2TH, United Kingdom
    Recruiting
  • Cambridge Clinical Research Centre
    Cambridge, CB2 0SL, United Kingdom
    Recruiting
  • NIHR Clinical Research Facility
    London, SE1 9RT, United Kingdom
    Recruiting
  • University College London Hospital - NIHR
    London, W1T 7HA, United Kingdom
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Sep 2026, 45 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 3, 2023
StartActual
Dec 19, 2022
Primary completionEst.
Sep 30, 2026
CompletionEst.
Dec 31, 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05669950
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Jan 3, 2023
Start date
Dec 19, 2022
Primary completion
Sep 30, 2026 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Email contact via H. Lundbeck A/S
Contact
HQ_Medinfo@Lundbeck.com
+45 36301311
Email contact via H. Lundbeck A/S
study director · HQ_Medinfo@Lundbeck.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asedebart

Start the discussion